



Boardroom Radio Interview

12 April 2011, Melbourne, Australia: Benitec Limited (ASX: BLT) provides the opportunity to listen to an audio broadcast of Dr Peter French, Chief Executive Officer, in a presentation entitled "Benitec patent outcomes underpin capital raising and company outlook - Dr Peter French CEO".

To listen to the broadcast, copy the following details into your web browser:

brr.com.au/event/78794

For Further Information

Dr Peter French
Chief Executive Officer
Tel: +61 (0)412 457 595

pfrench@benitec.com

Media enquiries:
College Hill Life Sciences
Sue Charles (Global)
Daniel Gooch (Europe)
Tel: +44 (0)20 7866 7866

benitec@collegehill.com

Andrew Geddes (Australia)
Tel: +61 (0)408 677 734

Rebecca Skye Dietrich (US)
Tel: +1 (857) 241 0795

About Benitec www.benitec.com

Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licenses from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian stock exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.